Anaconda Biomed today announced the closing of a US$56 million financing round with participation from new and existing investors. Proceeds will support product development and clinical work, including completion of the ongoing ATHENA pivotal investigational device exemption (IDE) study—a prospective, randomised, 327-subject trial intended to evaluate the safety and performance of the company’s Ana funnel catheter.
Omega Funds led the financing round, along with Spain’s co-investment fund (FOCO)—managed by COFIDES—as a new investor, and continued participation from Asabys, Ysios Capital, and CDTI through its SICC Innvierte.
“This latest funding round allows us to further advance our work in the acute treatment of those suffering a stroke, with the goal of reducing disability and death caused by large vessel occlusive disease,” said Trent Reutiman, chief executive officer (CEO) of Anaconda. “The support of this leading group of investors reflects the growing confidence in our technology platform, and the funds raised will ensure that the company has the required resources to complete the clinical and regulatory requirements. We sincerely appreciate the commitment of this prestigious group of investors.”
“Anaconda is bringing a next-generation solution to the large and growing ischaemic stroke market,” added Claudio Nessi, managing director of Omega Funds. “For millions of patients around the world, its portfolio of products offers hope for better treatment outcomes. With a very strong team, led by Trent Reutiman, we believe that Anaconda has the resources and unique technology to establish itself in the very active interventional neurovascular device market.”
Anaconda’s proprietary funnel catheter platform is a novel endovascular technology designed to improve clot capture, reduce embolic complications and maximise brain reperfusion. According to the company, in combining aspiration power with flow arrest and flow reversal, the platform may address clot retrieval, fragmentation and downstream embolisation, potentially tackling “thrombectomy’s most persistent challenges”.
Anaconda also notes that its product portfolio will include supplementary tools like stent retrievers, sheaths and guidewires designed to complement the use of the funnel catheter technology, and pave the way for additional clinical applications.
